Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAmotiv Limited

Amotiv Limited

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-11-04T21:03:54.107890Z
Market Cap
576.83M

Momentum Score

…

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
5.50
Low
7.74
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Amotiv Limited (AOV.TO) is a Toronto‑listed company for which public disclosures do not clearly describe its operating business or material assets; investors should consult the company's regulatory filings for definitive information. Long‑term growth drivers cannot be confirmed from public sources and would depend on the company's disclosed strategy, asset development and ability to secure capital, and investors may benefit if management establishes transparent operations and consistent revenue generation.

The principal investment risks are limited public disclosure and low trading liquidity, together with execution and financing risk if additional capital is required to implement the company's strategy.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.26
Dividend Yield
-
Revenue TTM
332.21M
Revenue Per Share
3.17
Gross Profit TTM
138.06M
Debt / Equity
0.09
ROE
-2.21%
Net Debt
3.10M
ROCE
-0.27%
Diluted EPS TTM
-0.16

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -6.70M 2.05M -21.99M -43.96M 6.69M
Minority interest - - - - 0.00M
Net income -5.37M 4.33M -16.84M -29.89M 15.68M
Selling general administrative 124.11M 99.35M 83.69M 40.15M 37.16M
Selling and marketing expenses - - - 48.47M 37.22M
Gross profit 207.70M 174.41M 152.65M 138.06M 115.41M
Reconciled depreciation - - 50.40M 62.62M 47.91M
Ebit - - - -2.40M -5.32M
Ebitda - - - 60.22M 42.59M
Depreciation and amortization - - - 62.62M 47.91M
Operating income -2.35M 7.40M 0.41M -2.40M -5.32M
Other operating expenses - - - 310.62M 256.31M
Interest expense - - 12.49M 6.60M 3.62M
Tax provision -1.33M -2.28M -5.15M -14.07M -8.98M
Interest income 4.70M 16.23M 28.50M 15.76M 14.04M
Net interest income - - 0.09M 4.03M 3.76M
Income tax expense - - - -14.07M -8.98M
Total revenue 450.09M 371.30M 328.20M 293.56M 243.48M
Total operating expenses 452.44M - 321.83M 155.12M 128.24M
Cost of revenue 242.38M 196.90M 175.55M 155.50M 128.07M
Total other income expense net - - -28.45M -41.56M 12.01M
Net income from continuing ops - - -16.84M -29.89M 15.68M
Net income applicable to common shares -5.37M 4.33M -16.84M -29.89M 15.68M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1046.30M 963.80M 945.49M 1054.84M 991.89M
Intangible assets 379.51M 283.61M 289.96M 338.78M 350.30M
Other current assets - 0.00M - 1.70M 4.51M
Total liab 279.03M 168.69M 198.62M 228.98M 149.87M
Total stockholder equity 767.27M 795.11M 746.87M 825.86M 842.02M
Other current liab - - 1.05M 15.01M 11.72M
Common stock 530.14M 534.27M - 599.05M 628.85M
Capital stock - - 540.05M 599.05M 628.85M
Retained earnings 148.94M 154.91M 150.89M 161.75M 191.65M
Other liab - - - - 31.89M
Good will 89.98M 86.48M 79.84M 82.27M 75.40M
Other assets 35.80M 28.46M - 15.60M 57.05M
Cash 71.09M 74.99M 58.76M 71.68M 85.96M
Cash and equivalents 5.35M 5.11M - 0.30M 9.03M
Total current liabilities 165.26M 111.25M 114.03M 141.32M 105.30M
Net debt - - 3.10M 6.02M -45.01M
Short term debt 0.00M 0.00M - 20.25M 28.28M
Short long term debt - - 17.85M 17.67M 26.66M
Short long term debt total - - - 77.70M 40.96M
Other stockholder equity 59.58M 79.99M - 23.78M 21.89M
Property plant equipment 21.93M 20.02M - 22.63M 29.94M
Total current assets 394.83M 396.81M 365.12M 395.62M 307.32M
Long term investments - - 120.02M 158.02M 178.95M
Net tangible assets - - - - 416.32M
Short term investments 37.78M 83.02M 111.41M 119.54M 77.03M
Net receivables 127.78M 105.20M 88.72M 110.20M 67.41M
Long term debt 51.16M 25.90M 44.02M 52.40M 9.27M
Inventory 135.87M 102.70M 91.83M 92.49M 72.40M
Accounts payable - - 85.37M 106.06M 65.31M
Accumulated other comprehensive income - - - 41.27M -0.38M
Non currrent assets other - - - 48.20M 47.93M
Non current assets total - - 580.38M 659.22M 684.57M
Capital lease obligations - - 7.22M 7.63M 5.03M
Long term debt total 57.78M 29.33M - 57.45M 12.68M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - 29.34M -63.08M 85.29M
Change to liabilities - - - 0.00M 11.46M
Total cashflows from investing activities -75.16M 16.96M 29.34M -63.08M -105.28M
Net borrowings - - - - -14.19M
Total cash from financing activities 5.41M -33.54M -81.00M 1.76M -78.31M
Change to operating activities - - - -5.41M 2.00M
Net income -5.37M 4.33M -16.84M -29.89M 15.68M
Change in cash -3.66M 21.34M -12.92M -14.28M -143.63M
Begin period cash flow - 58.76M 71.68M 85.96M 229.59M
End period cash flow - - 58.76M 71.68M 85.96M
Total cash from operating activities 68.96M 36.28M 35.94M 40.48M 44.62M
Depreciation 56.57M 53.11M 50.40M 62.62M 47.91M
Other cashflows from investing activities -41.46M 48.44M 39.30M -37.26M 30.93M
Dividends paid - - 0.00M 0.00M -
Change to inventory - - 0.70M -11.43M -17.19M
Change to account receivables - - 5.25M -26.42M 8.59M
Sale purchase of stock -6.35M -8.29M -53.48M -30.07M -64.42M
Other cashflows from financing activities -6.87M -7.20M -9.50M 52.12M 9.72M
Change to netincome - - - 17.74M -16.96M
Capital expenditures 33.69M 31.47M 9.96M 25.82M 224.18M
Change in working capital 1.89M -19.62M -26.90M -9.99M 0.63M
Stock based compensation - - 2.33M 1.89M 3.04M
Other non cash items - - 10.30M 32.98M -15.01M
Free cash flow - - 25.98M 14.66M -179.56M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CURA
Curaleaf Holdings Inc.		 -0.74
5.20%		 13.49 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.31
2.72%		 11.72 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.16
3.36%		 4.92 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.41
11.02%		 4.13 - 1000.00 1.28 0.53 1.08 -2.30

Profile*

Amotiv Limited

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

3400 de Maisonneuve Boulevard West, Montreal, QC, Canada, H3Z 3B8

514-484-4483

https://www.gud-knight.com

725

Name Title Year Born
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A. Executive Chairman 1969
Ms. Samira Sakhia BCom, CA, CPA, MBA President, CEO & Director 1968
Mr. Arvind Utchanah Chief Financial Officer NA
Ms. Amal Khouri B.Sc., M.B.A. Chief Business Officer NA
Mr. Jeff Martens Global Vice President of Commercial NA
Mr. Stephani Saverio Vice President of Business Development NA
Mr. Leopoldo Bosano Vice-President of Manufacturing & Operations NA
Ms. Monica Percario Global Vice President of Scientific Affairs NA
Mr. Henrique Dias Global Director of Marketing NA
Ms. Susan Caroline Emblem Global Vice President of Human Resources NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…